In this study, participants aged 55-74 years old, who had history of cigarette smoking >30 years or former smokers who had quit within 15 years were screened using low-dose CT (LDCT) or CXR, yearly for three consecutive years.
Those who had yearly LDCT screening had higher number of lung cancer diagnosed when compared with screening using CXR only.
Conversely, the lung cancer specific mortality was lower in the LDCT screening group.
The reasons are simply because those who had LDCT screenings had
- more lung cancers diagnosed at earlier stage (stage 1: 50% vs 31%) and
- lesser patients diagnosed at later stage (stage 3&4: 43% vs 61%).
In conclusion, although the absolute risk reduction was just 3 in 1000 or the number needed to screen to prevent one lung cancer specific death is 330 (1/0.003).
For the government, it’s not cost-effective to implement LDCT due to the large number of patients needed to be screened just to prevent one lung cancer specific death.
However, if you fall into the above risk group and can afford to pay for your own LDCT screening, you can reduce the risk of death by 20% for your own self.
Else, just can a CXR done. It can still play an important role to detect lung cancer at an earlier stage. #lungcancer #drbhnglatest
There are active research being conducted using tumour auto-antibodies (TAA) and circulating tumor cells as complementary tools to improve early detection of lung cancer.
Tumour auto-antibodies had been found to be present even before the disease became symptomatic.
Currently, there are using a panel of seven tumour auto-antibody and the results from their study was very impressive, with positive predictive value of 95%!